Programmed Cell Death Protein-1 Regulation in Response to SARS-CoV-2 in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2: A Prospective Cohort Study

• Published in: International journal of molecular sciences 2024-06, Vol.25 (11), p.5968
• Main Authors: Opoka-Winiarska, Violetta, Grywalska, Ewelina, Morawska-Michalska, Izabela, Korona-Głowniak, Izabela, Kądziołka, Olga, Gosik, Krzysztof, Majchrzak, Adam, Rahnama-Hezavah, Mansur, Niedźwiedzka-Rystwej, Paulina
• Format: Article
• Language: English
• Subjects: Adolescent; Apoptosis; Arthritis; B cells; Biochemistry; CD4-Positive T-Lymphocytes - immunology; CD4-Positive T-Lymphocytes - metabolism; CD8-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - metabolism; Cell death; Child; Child, Preschool; Communication; COVID-19; COVID-19 - blood; COVID-19 - complications; COVID-19 - immunology; COVID-19 - metabolism; Cytokines; Development and progression; Disease; Ethylenediaminetetraacetic acid; Female; Fever; Health aspects; Hepatitis; Humans; Immune system; Immunoglobulins; Immunology; immunophenotype; Immunophenotyping; Infant; Infection; Infections; Ligands; lymphocyte; Lymphocytes; Male; Multisystem inflammatory syndrome in children; Paediatric Multisystem Inflammatory Syndrome; Pandemics; Pathogenesis; Pediatrics; Programmed Cell Death 1 Receptor - metabolism; programmed cell death protein 1; Prospective Studies; Proteins; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Systemic Inflammatory Response Syndrome - blood; Systemic Inflammatory Response Syndrome - diagnosis; T cells
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25115968

The role of programmed death cell protein 1 (PD-1) has already been described in a range of various diseases, including COVID-19. This study provides new, innovative data, related to the expression of PD-1 and the risk of Paediatric Inflammatory Multisystem Syndrome, temporally associated with SARS-CoV-2 infection (PIMS-TS)-a rare, but potentially life-threatening complication of COVID-19. In this study, we evaluated the expression of PD-1 protein in patients with PIMS. Blood samples were taken from patients at the time of diagnosis (n = 33), after 6 weeks (n = 33), 3 months (n = 24), 6 months (n = 24) and 12 months (n = 8). The immunophenotypes were evaluated in flow cytometry. The control group consisted of 35 healthy children with negative SARS-CoV-2 antigen/PCR test, who were asymptomatic and had no history of allergic, autoimmune or oncological diseases. The associations between immunophenotypes, biochemical findings and clinical data were analysed. Significant increases in the expression of PD-1 for CD4+ and CD8+ T cells, compared to the control group, were observed in the day of admission, with a gradual decrease during the first weeks from initiation of treatment. This study sheds new light on the pathogenesis of PIMS-TS, emphasizing the role of PD-1 protein. Future research is essential for early risk prediction in SARS-CoV-2 patients and for devising effective clinical prevention and management strategies.